{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"7.8","value":"6.3"},{"groupId":"OG001","lowerLimit":"9.1","upperLimit":"13.0","value":"11.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"155"}],"units":"Participants"}],"title":"Teff-high WT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"7.0","value":"6.3"},{"groupId":"OG001","lowerLimit":"7.7","upperLimit":"9.8","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"356"}],"units":"Participants"}],"title":"ITT-WT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"356"}],"units":"Participants"}],"description":"PFS, as determined by the investigator according to RECIST v1.1, in Arm A versus B in the Teff high-WT population and ITT-WT population.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG001","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)","title":"PFS, as Determined by the Investigator in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population","type":"SECONDARY","unitOfMeasure":"Months"}